Ashkon Software



EARS - Auris Medical Holding AG

Auris Medical Holding AG logo Auris Medical Holding AG (EARS) is a Swiss clinical-stage biopharmaceutical company that is focused on developing treatments for inner ear disorders. The company's lead product candidate is AM-101, a drug designed to treat acute inner ear tinnitus, which is characterized by a ringing or buzzing in the ears.

Auris Medical is also developing other product candidates, including AM-111, a drug designed to treat acute inner ear hearing loss, and AM-125, a drug designed to treat vertigo and dizziness associated with Meniere's disease.

Auris Medical was founded in 2003 and is headquartered in Zug, Switzerland. The company was conducting clinical trials for its product candidates and had not yet generated significant revenue. The company's revenue for the fiscal year 2020 was $0.6 million, representing a decline from $0.9 million in the previous year. Net loss for the same period was $9.9 million, a decline from a net loss of $17.4 million in the previous year.

Auris Medical has a market capitalization of approximately $5 million as of my knowledge cutoff of September 2021, and its stock is listed on the NASDAQ stock exchange under the ticker symbol EARS.

The biopharmaceutical industry is subject to various risks, including regulatory risks, competitive risks, and clinical trial risks. However, Auris Medical's focus on developing treatments for inner ear disorders and its efforts to advance its product candidates through clinical trials should position it for improved performance in




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer